Education
About Us
Working with TipRanks
Follow Us
Larimar Therapeutics, Inc. (LRMR)
NASDAQ:LRMR
LRMR Stock Chart & Stats
$3.36
-$0.11(-2.78%)
At close: 4:00 PM EST
$3.36
-$0.11(-2.78%)
Day’s Range― - ―
52-Week Range$1.61 - $5.37
Previous CloseN/A
Volume147.46K
Average Volume (3M)1.19M
Market Cap
$292.72M
Enterprise Value$81.90M
Total Cash (Recent Filing)$175.44M
Total Debt (Recent Filing)$4.35M
Price to Earnings (P/E)―
Beta1.92
Next Earnings
Mar 18, 2026EPS Estimate
-0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.61
Shares Outstanding85,590,390
10 Day Avg. Volume681,515
30 Day Avg. Volume1,191,223
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)1.38
Price to Sales (P/S)0.00
P/FCF Ratio-3.33
Enterprise Value/Market Cap0.28
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-468.01
Enterprise Value/Ebitda-0.60
Forecast
1Y Price Target
$21.50Price Target Upside539.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And Surrogate BiomarkerNomlabofusp increased skin frataxin to about half of healthy levels in all evaluable participants by six months, supporting skin frataxin as a surrogate endpoint and indicating potential disease-modifying effect pending randomized confirmation.
Physician Acceptance And Adoption PotentialHigh prescriber comfort with nomlabofusp's risk–benefit profile despite anaphylaxis suggests clinicians may adopt the therapy where unmet need is high, supporting commercial uptake prospects.
Regulatory Pathway And TimingInclusion in the FDA START program and ongoing agency interactions, along with a planned BLA submission under an accelerated approval pathway in Q2 2026, provides regulatory clarity that could boost investor confidence.
Bears Say
Evidentiary Standard And Regulatory SkepticismFDA questioning of external natural history comparisons in related programs increases the risk that efficacy may need randomized functional data for approval, raising the bar for nomlabofusp.
Market Sensitivity To Peer Regulatory SetbacksShare weakness driven by negative regulatory news at peer companies highlights market sensitivity to industry-wide regulatory developments, which can amplify downside for the stock.
Safety Risk From AnaphylaxisMultiple anaphylaxis events, often occurring at first exposure and within weeks of starting treatment, represent a significant safety concern that could limit use and complicate regulatory assessment.
Larimar Therapeutics News
LRMR FAQ
What was Larimar Therapeutics, Inc.’s price range in the past 12 months?
Larimar Therapeutics, Inc. lowest stock price was $1.61 and its highest was $5.37 in the past 12 months.
What is Larimar Therapeutics, Inc.’s market cap?
Larimar Therapeutics, Inc.’s market cap is $292.72M.
When is Larimar Therapeutics, Inc.’s upcoming earnings report date?
Larimar Therapeutics, Inc.’s upcoming earnings report date is Mar 18, 2026 which is in 68 days.
How were Larimar Therapeutics, Inc.’s earnings last quarter?
Larimar Therapeutics, Inc. released its earnings results on Nov 05, 2025. The company reported -$0.61 earnings per share for the quarter, missing the consensus estimate of -$0.404 by -$0.206.
Is Larimar Therapeutics, Inc. overvalued?
According to Wall Street analysts Larimar Therapeutics, Inc.’s price is currently Undervalued.
Does Larimar Therapeutics, Inc. pay dividends?
Larimar Therapeutics, Inc. does not currently pay dividends.
What is Larimar Therapeutics, Inc.’s EPS estimate?
Larimar Therapeutics, Inc.’s EPS estimate is -0.49.
How many shares outstanding does Larimar Therapeutics, Inc. have?
Larimar Therapeutics, Inc. has 85,590,390 shares outstanding.
What happened to Larimar Therapeutics, Inc.’s price movement after its last earnings report?
Larimar Therapeutics, Inc. reported an EPS of -$0.61 in its last earnings report, missing expectations of -$0.404. Following the earnings report the stock price went down -15.263%.
Which hedge fund is a major shareholder of Larimar Therapeutics, Inc.?
Currently, no hedge funds are holding shares in LRMR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Larimar Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.50 (539.88% Upside)
$21.50 (539.88% Upside)
Blogger Sentiment
Bullish
LRMR Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 10.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 6.7%
Last 30 Days ▼ 6.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-13.63%
12-Months-Change
Fundamentals
Return on Equity
-78.24%
Trailing 12-Months
Asset Growth
-14.46%
Trailing 12-Months
Company Description
Larimar Therapeutics, Inc.
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
LRMR Stock 12 Month Forecast
Average Price Target
$21.50
▲(539.88% Upside)
Technical Analysis
Omeros
―
Vanda
―
Foghorn Therapeutics
―
Candel Therapeutics
―
Neumora Therapeutics, Inc.
―
Ownership Overview
Currently, No data available
---